Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 11/20 | 0.64 |
| ▸ | AR | P10275 | 9/20 | 0.64 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | SHBG | P04278 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3763162 | 1.00 | PGR (0.64) | PGRARNR3C2CYP19A1LMNA | |
| SCHEMBL16564430 | 0.89 | PGR (0.63) | PGRARNR3C2CYP19A1LMNA | |
| SCHEMBL16564562 | 0.89 | PGR (0.63) | PGRARNR3C2CYP19A1LMNA | |
| SCHEMBL3763967 | 0.88 | PGR (0.54) | PGRARNR3C2CYP19A1LMNA | |
| SCHEMBL3768624 | 0.88 | PGR (0.54) | PGRARNR3C2CYP19A1LMNA | |
| SCHEMBL13556648 | 0.87 | PGR (0.64) | PGRARNR3C2CYP19A1LMNA | |
| SCHEMBL3763146 | 0.83 | PGR (0.46) | PGRARNR3C2CYP19A1LMNA | |
| SCHEMBL13768841 | 0.83 | PGR (0.66) | PGRARNR3C2CYP19A1LMNA | |
| SCHEMBL3763087 | 0.83 | PGR (0.58) | PGRARCYP19A1LMNACYP3A4 | |
| SCHEMBL3763965 | 0.81 | PGR (0.60) | PGRARLMNACYP3A4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987239-B2 | 19-nor-steroid derivatives with a 15α,16α-methylene group and a saturated 17,17-spirolactone ring, use thereof, and medicaments containing said derivatives | Bayer Intellectual Property GbmH (DE) | 2015-03-24 | — | — | US | claimed |
| EP-2238149-B1 | 19-NOR-STEROID DERIVATIVES WITH A 15ALPHA, 16ALPHA-METHYLENE GROUP AND A SATURATED 17,17-SPIROLACTONE RING, USE THEREOF, AND MEDICAMENTS CONTAINING SAID DERIVATIVES | BAYER IP GMBH (DE) | 2015-03-18 | — | — | EP | claimed |
| US-20130123219-A1 | 19-NOR-STEROID DERIVATIVES WITH A 15a,16a-METHYLENE GROUP AND A SATURATED 17,17-SPIROLACTONE RING, USE THEREOF, AND MEDICAMENTS CONTAINING SAID DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-16 | — | — | US | claimed |
| US-20100311702-A1 | 19-NOR-STEROID DERIVATIVES WITH A 15ALPHA, 16ALPHA-METHYLENE GROUP AND A SATURATED 17, 17-SPIRO-LACTONE RING, USE THEREOF, AND MEDICAMENTS CONTAINING SAID DERIVATIVES | BAYER SCHERING PHARMA AKTEINGESELLSCHAFT (DE) | 2010-12-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311702-A1 | 19-NOR-STEROID DERIVATIVES WITH A 15ALPHA, 16ALPHA-METHYLENE GROUP AND A SATURATED 17, 17-SPIRO-LACTONE RING, USE THEREOF, AND MEDICAMENTS CONTAINING SAID DERIVATIVES | HSD17B7, CYP17A1, NR3C2 | PGR 57/4885AR 58/4885NR3C2 3/4885 |
| US-20130123219-A1 | 19-NOR-STEROID DERIVATIVES WITH A 15a,16a-METHYLENE GROUP AND A SATURATED 17,17-SPIROLACTONE RING, USE THEREOF, AND MEDICAMENTS CONTAINING SAID DERIVATIVES | HSD17B7, CYP17A1, NR3C2 | PGR 57/4885AR 33/4885NR3C2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.